Bex and Cile combinatorial effect on TCL dissemination. (A) Graphical representation of the in vivo metastatic models and treatment schedule including Veh, bexarotene with levothyroxine replacement (BexT4+), Cile alone, or Bex with levothyroxine and Cile (BexT4+Cile). (B) Quantification of the number of experimental metastases in the liver and kidneys in the different groups in EL4 in vivo model. (C) Representative photographs of the livers and kidneys from the mice of the different treatments. (D) Quantification of the number of experimental metastases in the lungs of the different groups of treatment in the CUTLL1 in vivo model. (E) Representative photographs of lungs and kidneys from NOD-SCID (arrows point to CUTLL1 micronodules). (F) Representative photographs of hematoxylin and eosin–stained lung, kidney, and liver tissues (n = 5 per group).